Tributary Capital Management LLC decreased its stake in Allergan PLC. (NYSE:AGN) by 3.6% during the second quarter, Holdings Channel reports. The firm owned 3,190 shares of the company’s stock after selling 120 shares during the period. Tributary Capital Management LLC’s holdings in Allergan PLC. were worth $775,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Verde Servicos Internacionais S.A. boosted its stake in Allergan PLC. by 22.0% in the first quarter. Verde Servicos Internacionais S.A. now owns 101,977 shares of the company’s stock valued at $24,364,000 after buying an additional 18,387 shares during the period. Horan Capital Management boosted its stake in Allergan PLC. by 21.4% in the first quarter. Horan Capital Management now owns 38,717 shares of the company’s stock valued at $9,250,000 after buying an additional 6,836 shares during the period. BKD Wealth Advisors LLC purchased a new stake in Allergan PLC. during the first quarter valued at $219,000. American National Bank boosted its stake in Allergan PLC. by 0.6% in the first quarter. American National Bank now owns 15,233 shares of the company’s stock valued at $3,640,000 after buying an additional 95 shares during the period. Finally, Atria Investments LLC boosted its stake in Allergan PLC. by 35.1% in the first quarter. Atria Investments LLC now owns 7,310 shares of the company’s stock valued at $1,747,000 after buying an additional 1,900 shares during the period. Institutional investors own 84.77% of the company’s stock.

Shares of Allergan PLC. (NYSE AGN) traded up 0.29% on Friday, hitting $232.88. 1,820,899 shares of the stock were exchanged. The company has a 50-day moving average price of $245.93 and a 200 day moving average price of $238.13. The company has a market cap of $77.85 billion, a PE ratio of 7.10 and a beta of 1.16. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80.

Allergan PLC. (NYSE:AGN) last released its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company’s revenue was up 8.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.35 EPS. Equities analysts forecast that Allergan PLC. will post $16.27 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be given a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.20%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio is presently 9.95%.

ILLEGAL ACTIVITY NOTICE: “Allergan PLC. (NYSE:AGN) Stake Decreased by Tributary Capital Management LLC” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/08/12/allergan-plc-nyseagn-stake-decreased-by-tributary-capital-management-llc.html.

AGN has been the subject of several recent analyst reports. Citigroup Inc. reiterated a “focus list” rating and set a $261.27 price objective (up from $184.50) on shares of Allergan PLC. in a research report on Friday, April 21st. Royal Bank Of Canada increased their price objective on shares of Allergan PLC. from $279.00 to $284.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 10th. Goldman Sachs Group, Inc. (The) cut shares of Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price objective for the company. in a research report on Wednesday, May 10th. UBS AG reiterated a “buy” rating and set a $275.00 price objective on shares of Allergan PLC. in a research report on Monday, May 15th. Finally, Sanford C. Bernstein reiterated an “outperform” rating on shares of Allergan PLC. in a research report on Thursday, May 25th. Eight analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $274.49.

In other news, Director Nesli Basgoz sold 1,889 shares of the company’s stock in a transaction dated Thursday, May 18th. The shares were sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.36% of the stock is owned by corporate insiders.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.